Update on the Use of Steroids in Rheumatoid Arthritis

详细信息    查看全文

• 作者：Blanca Garc¨ªa-Magall¨®n ; Luc¨ªa Silva-Fern¨¢ndez ; Jos¨¦ Luis Andreu-S¨¢nchez
• 关键词：Rheumatoid arthritis ; Corticosteroids ; Disease-modifying anti-rheumatic drugs
• 刊名：Reumatologa Clnica (English Edition)
• 出版年：2013
• 出版时间：September-October, 2013
• 年：2013
• 卷：9
• 期：5
• 页码：297-302
• 全文大小：609 K

文摘

Corticosteroids are a mainstay in the therapy of rheumatoid arthritis (RA). In recent years, a number of high-quality controlled clinical trials have shown their effect as a disease-modifying anti-rheumatic drug (DMARD) and a favorable safety profile in recent-onset RA. Despite this, they are more frequently used as bridge therapy while other DMARDs initiate their action than as true disease-modifying agents. Low-dose corticosteroid use during the first two years of disease slows radiologic damage and reduces the need of biologic therapy aimed at reaching a state of clinical remission in recent-onset RA. Thus, their systematic use in this clinical scenario should be considered.